Lupin announced the launch of a combination drug for patients suffering from heart failure (HF). Sacubitril and Valsartan have been introduced in India under two brand names, Valentas and Arnipin, in strengths of 200 mg, 100 mg, and 50 mg. According to the drug maker, HF is still one of the leading causes of death in patients with chronic heart failure in India, with an estimated prevalence ranging from 1.3 to 4.6 million.
Valentas and Arnipin are approved to reduce the need for repeat hospitalisations and the risk of cardiovascular death in adult patients with chronic mild to moderate heart failure.
“The launch of Valentas and Arnipin aligns with this commitment by providing patients with an important treatment option, filling an unmet need, and lowering the cost of therapy,” Lupin said.